Innovating.works Conecta tu I+D

Showing 1 to 20 of 87 results

ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE FONDAZIONE TELETHON ETS participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-07 The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare...
2024-08-20 - 2031-08-31 | Financiado

MENTOR: Metabolic control of cell growth by mTOR in health and disease a multi disciplinary training MENTOR is a multi-disciplinary training network which focuses on the mTOR pathway, a central mechanistic hub that integrates nutritional cue...
2024-07-09 - 2028-12-31 | Financiado

EXPEDITE: EXPanding AAV gene therapy by EDITing FONDAZIONE TELETHON ETS tramitó un HORIZON EUROPE: ERC-2022-ADG In vivo gene therapy based on a single administration of adeno-associated viral (AAV) vectors is emerging as an effective therapeutic option...
2023-08-31 - 2028-10-31 | Financiado

ProgRet: European Training Program to Understand, Diagnose and Treat Autosomal Dominant Retinal Diseases FONDAZIONE TELETHON ETS participó en un HORIZON EUROPE: HORIZON-MSCA-2022-DN-01 ProgRET will create a multidisciplinary and intersectoral European training network focusing on the mechanisms, diagnosis and therapy of dom...
2023-07-05 - 2027-12-31 | Financiado

INCANTAR: TARGETING INHERITED CANCER SYNDROMES FONDAZIONE TELETHON ETS tramitó un HORIZON EUROPE: ERC-2022-ADG Transcription factors EB and E3 (TFEB and TFE3), members of the MiT-TFE family, are master controllers of lysosomal biogenesis and autophagy...
2023-06-12 - 2028-08-31 | Financiado

IMMUTOL: ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED... FONDAZIONE TELETHON ETS tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which dampen inflammation, but do not stop the ca...
2023-04-14 - 2027-04-30 | Financiado

AAVolution: Next-generation AAV vectors for liver-directed gene therapy FONDAZIONE TELETHON ETS tramitó un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDERCHALLENGES-01 Liver-directed gene therapy has undergone significant development in the last two decades. Recombinant adeno-associated vectors (AAV) are th...
2022-10-01 - 2026-09-30 | Financiado

AAVolution: Next-generation AAV vectors for liver-directed gene therapy FONDAZIONE TELETHON ETS tramitó un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDERCHALLENGES-01 Liver-directed gene therapy has undergone significant development in the last two decades. Recombinant adeno-associated vectors (AAV) are th...
2022-07-11 - 2026-09-30 | Financiado

AUTO-SELECT: Dissect cargo selectivity in autophagy FONDAZIONE TELETHON ETS participó en un HORIZON EUROPE: ERC-2021-COG (Macro)autophagy is an evolutionarily conserved catabolic process induced to preserve cellular homeostasis under conditions of stress, such...
2022-05-10 - 2027-12-31 | Financiado

RE-STORE: Pharmacological restoration of selective autophagy for the treatment of skeletal disorders FONDAZIONE TELETHON ETS tramitó un H2020: ERC-2020-PoC Lysosomal storage disorders (LSDs) are a family of inherited genetic diseases characterized by lysosomal dysfunction, with a consequent bloc...
2020-12-12 - 2022-06-30 | Financiado

IC2PerMed: Integrating China in the International Consortium for Personalised Medicine FONDAZIONE TELETHON ETS participó en un H2020: H2020-SC1-BHC-2018-2020 Personalised Medicine (PM) approaches, thanks to the latest technological advances notably in the fields of biomedical and digital technolog...
2019-12-12 - 2023-12-31 | Financiado

inSight: Moving a novel gene therapy paradigm to treat blindness to the market FONDAZIONE TELETHON ETS participó en un H2020: ERC-2018-PoC At present therapies for inherited dominant disorders are not available, thus representing an urgent unmet medical and social need. The ERC...
2019-05-17 - 2021-05-31 | Financiado

RESTORE: RESTORE Health by Advanced Therapies Advanced Therapy Medicinal Products and Biologized Medical Dev... FONDAZIONE TELETHON ETS participó en un H2020: H2020-FETFLAG-2018-2020 Recently, a new class of living drugs has been developed – Advanced Therapies which aim to transform the current focus of treatment of disea...
2019-02-08 - 2020-07-31 | Financiado

UPGRADE: Unlocking Precision Gene Therapy FONDAZIONE TELETHON ETS tramitó un H2020: H2020-SC1-BHC-2018-2020 Gene therapy has recently shown remarkable potential to offer definitive treatments for otherwise incurable diseases. Currently, seven gene...
2018-12-04 - 2024-06-30 | Financiado